Perpetual Ltd Sells 77,125 Shares of Koninklijke Philips (NYSE:PHG)

Perpetual Ltd reduced its stake in shares of Koninklijke Philips (NYSE:PHG - Free Report) by 6.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,100,563 shares of the technology company's stock after selling 77,125 shares during the quarter. Perpetual Ltd owned 0.12% of Koninklijke Philips worth $27,866,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Mitchell & Pahl Private Wealth LLC grew its holdings in Koninklijke Philips by 6.6% in the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 35,894 shares of the technology company's stock worth $909,000 after acquiring an additional 2,213 shares during the last quarter. Aaron Wealth Advisors LLC boosted its holdings in shares of Koninklijke Philips by 19.2% during the fourth quarter. Aaron Wealth Advisors LLC now owns 9,208 shares of the technology company's stock worth $233,000 after purchasing an additional 1,483 shares during the period. Legacy Wealth Asset Management LLC grew its stake in shares of Koninklijke Philips by 1.1% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 51,331 shares of the technology company's stock worth $1,300,000 after purchasing an additional 562 shares during the last quarter. Park Avenue Securities LLC increased its holdings in Koninklijke Philips by 16.8% during the 4th quarter. Park Avenue Securities LLC now owns 19,867 shares of the technology company's stock valued at $503,000 after purchasing an additional 2,862 shares during the period. Finally, Bar Harbor Wealth Management raised its position in Koninklijke Philips by 2.1% during the 4th quarter. Bar Harbor Wealth Management now owns 308,157 shares of the technology company's stock valued at $7,803,000 after purchasing an additional 6,281 shares during the last quarter. Hedge funds and other institutional investors own 13.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group upgraded Koninklijke Philips from an "underperform" rating to a "hold" rating in a research report on Tuesday, October 29th. StockNews.com cut shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a report on Thursday, November 14th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, Koninklijke Philips currently has a consensus rating of "Hold".

Koninklijke Philips Stock Up 2.9 %

Shares of PHG stock traded up $0.75 during midday trading on Tuesday, reaching $26.55. 626,695 shares of the stock were exchanged, compared to its average volume of 517,325. The firm has a market cap of $24.95 billion, a PE ratio of -63.21, a price-to-earnings-growth ratio of 0.86 and a beta of 0.77. The company has a current ratio of 1.16, a quick ratio of 0.74 and a debt-to-equity ratio of 0.60. The company's 50 day moving average is $25.84 and its two-hundred day moving average is $28.09. Koninklijke Philips has a 1 year low of $19.55 and a 1 year high of $32.91.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.